Clifford A. Hudis, MD: A Message From ASCO’s CEO
2024 ASCO Annual Meeting
Clifford A. Hudis, MD, of the American Society of Clinical Oncology (ASCO), talks about the 2024 Annual Meeting, and a focus on the compassionate side of cancer care.
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Welcome, everybody, to the 60th Annual ASCO Meeting. This meeting is an especially meaningful and exciting one for me because this comes on the heels of decades of really powerful advances across all of oncology, including, of course, targeted therapy, small molecules, immunotherapy, and engineered cells, among many other advances that I'd say in the last five to 10 years have truly transformed oncology. But what makes this year's meetings especially exciting, is that we have coupled this with a call for humanism in medicine and a reminder of the privilege of caring for patients and families through this most difficult time. Our president, Dr. Lynn Schuchter, who's been on the leading edge of the most exciting advances in cancer, especially those in melanoma, at the same time is one of the most compassionate, holistic kinds of physicians anyone could hope to see, and she brings that with passion to this meeting. So we're very, very excited by the inclusion of so many new resources and learnings for our community to help them help their patients around the world more effectively than ever before.
The ASCO Post Staff
Ana C. Garrido-Castro, MD, of Dana-Farber Cancer Institute, discusses recent approvals of multiple novel therapies for metastatic breast cancer, weighing their potential benefits and risks, understanding the mechanisms that drive response and resistance, and exploring how to optimally sequence them to enhance survival and quality of life.
The ASCO Post Staff
Jens Marquardt, MD, of the University of Lübeck, and Jens Hoeppner, MD, of the University of Bielefeld, discuss findings from the ESOPEC trial, which showed that perioperative chemotherapy (fluorouracii, leucovorin, oxaliplatin, docetaxel) and surgery improves survival in patients with resectable esophageal adenocarcinoma when compared with neoadjuvant chemoradiation (41.4 Gy plus carboplatin and paclitaxel) followed by surgery (LBA1).
The ASCO Post Staff
Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, and Thomas Powles, MD, PhD, of Barts Cancer Institute and the University of London, discuss phase III findings from two studies: the first, investigating enfortumab vedotin-ejfv and pembrolizumab vs platinum-based chemotherapy in previously untreated patients with locally advanced or metastatic urothelial cancer; and the second, looking at nivolumab plus gemcitabine and cisplatin vs gemcitabine and cisplatin alone in patients with lymph node–only metastatic disease enrolled in the CheckMate 901 trial (Abstracts 4581 and 4565).
The ASCO Post Staff
Efrat Dotan, MD, of Fox Chase Cancer Center, discusses results from the phase II EA2186 trial, the first prospective study aiming to define the optimal treatment approach for vulnerable older adults with newly diagnosed metastatic pancreatic cancer (Abstract 4003).
The ASCO Post Staff
Yucai Wang, MD, PhD, of the Mayo Clinic, discusses the increased efficacy of combination therapy with pembrolizumab plus a BCR kinase inhibitor compared with pembrolizumab alone in patients with Richter transformation of chronic lymphocytic leukemia (CLL; Abstract 7050).
